Equity Profile

NBIX

Neurocrine Biosciences, Inc.

Health CareBiotechnology$16.1B

May5Tue

Post-Earnings Recap

ReportedQ1-2026After Close4:01 PM EDT

Neurocrine Biosciences Beats on EPS, Stock Up 0.74%

Metric	Actual	Expected	Surprise
EPS	$1.94	$1.71	+51.21%
Revenue	—	$771M	—

management commentary, guidance changes, and full analysis available with Pro.

Neurocrine Biosciences Beats on EPS, Stock Up 0.74%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$1.94	$1.71	+51.21%
Revenue	—	$771M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Neurocrine Biosciences reported a strong earnings per share, significantly beating expectations, which contributed to a slight increase in stock price. However, there was no revenue reported, leaving some uncertainty about overall performance. The lack of guidance and management commentary means investors may need to wait for further details to assess future prospects.

Company Snapshot

Neurocrine Biosciences, Inc. (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.

$1.71

Revenue

Total revenue reflects the company's ability to sell its products and is crucial for assessing growth and market demand.

$771M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Neurocrine Biosciences, Inc. (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine diseases. With a market cap of $13 billion, it plays a significant role in the healthcare sector, particularly as demand for innovative therapies continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.15%

Avg Stock Reaction

+2.03%

Last Quarter Recap

In Q4 2025, Neurocrine reported an EPS of $1.88, exceeding expectations by 5.56%. However, the stock experienced a slight decline the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Neurocrine to continue its trend of strong earnings, with a consensus EPS of $1.71 and revenue of $771 million. Investors are keen to see if the company can maintain its positive momentum.

Bull Case

If Neurocrine beats EPS and revenue estimates, it could signal strong demand for its products and further validate its growth strategy, potentially boosting investor confidence.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth trajectory and market competitiveness, leading to a negative reaction in the stock price.

Key Metrics to Watch

EPS

$1.71

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.

Revenue

$771M

Total revenue reflects the company's ability to sell its products and is crucial for assessing growth and market demand.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed $1.71, and if so, by how much?

A strong EPS performance could reinforce investor confidence and suggest robust demand for Neurocrine's products.

What is the revenue outlook for the upcoming quarters?

Guidance on revenue will be crucial for assessing the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Neurocrine's new product pipeline to drive revenue growth beyond current projections.

Supporting Evidence

Historical performance shows a consistent ability to exceed EPS estimates, suggesting a strong operational foundation.

The options market indicates heightened expectations for volatility, which could reflect investor optimism not fully captured in analyst estimates.

Key Risk

If revenue growth significantly outpaces expectations, it could challenge the current consensus view.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching how Neurocrine's performance aligns with analyst expectations, particularly in a competitive biotech landscape.

Bull Confirmed If

An EPS of $1.80 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $1.50 would raise concerns about profitability and growth potential.

Pre-Earnings Positioning

Options Market

Implied Move

±10.95%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±10.2% while NBIX has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

27.4%

Calls (4K)P/C Ratio: 0.37Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Neurocrine beats expectations, history suggests a positive stock reaction, averaging a +2.44% move.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors assess management's commentary.

Miss

A miss could lead to a negative reaction, with historical averages suggesting a decline of around -2.44%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of new product launches.
2Any changes in guidance regarding future revenue projections.
3Insights into market demand for Neurocrine's therapies.
4Management's commentary on competitive positioning.
5Details on research and development progress for upcoming treatments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Neurocrine Biosciences, Inc. (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.

$1.71

Revenue

Total revenue reflects the company's ability to sell its products and is crucial for assessing growth and market demand.

$771M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.15%

Avg Stock Reaction

+2.03%

Last Quarter Recap

In Q4 2025, Neurocrine reported an EPS of $1.88, exceeding expectations by 5.56%. However, the stock experienced a slight decline the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Neurocrine beats EPS and revenue estimates, it could signal strong demand for its products and further validate its growth strategy, potentially boosting investor confidence.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth trajectory and market competitiveness, leading to a negative reaction in the stock price.

Key Metrics to Watch

EPS

$1.71

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.

Revenue

$771M

Total revenue reflects the company's ability to sell its products and is crucial for assessing growth and market demand.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed $1.71, and if so, by how much?

A strong EPS performance could reinforce investor confidence and suggest robust demand for Neurocrine's products.

What is the revenue outlook for the upcoming quarters?

Guidance on revenue will be crucial for assessing the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for Neurocrine's new product pipeline to drive revenue growth beyond current projections.

Supporting Evidence

Historical performance shows a consistent ability to exceed EPS estimates, suggesting a strong operational foundation.

The options market indicates heightened expectations for volatility, which could reflect investor optimism not fully captured in analyst estimates.

Key Risk

If revenue growth significantly outpaces expectations, it could challenge the current consensus view.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching how Neurocrine's performance aligns with analyst expectations, particularly in a competitive biotech landscape.

Bull Confirmed If

An EPS of $1.80 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $1.50 would raise concerns about profitability and growth potential.

Pre-Earnings Positioning

Options Market

Implied Move

±10.95%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±10.2% while NBIX has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

27.4%

Calls (4K)P/C Ratio: 0.37Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Neurocrine beats expectations, history suggests a positive stock reaction, averaging a +2.44% move.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors assess management's commentary.

Miss

A miss could lead to a negative reaction, with historical averages suggesting a decline of around -2.44%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of new product launches.
2Any changes in guidance regarding future revenue projections.
3Insights into market demand for Neurocrine's therapies.
4Management's commentary on competitive positioning.
5Details on research and development progress for upcoming treatments.